alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<RESTATED> 
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                           4,734
<SECURITIES>                                       986
<RECEIVABLES>                                   18,781
<ALLOWANCES>                                       387
<INVENTORY>                                          0
<CURRENT-ASSETS>                                25,721
<PP&E>                                           6,881
<DEPRECIATION>                                   2,213
<TOTAL-ASSETS>                                  33,720
<CURRENT-LIABILITIES>                           15,237
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        20,352
<OTHER-SE>                                     (3,009)
<TOTAL-LIABILITY-AND-EQUITY>                    33,720
<SALES>                                         60,444
<TOTAL-REVENUES>                                60,444
<CGS>                                                0
<TOTAL-COSTS>                                   34,435
<OTHER-EXPENSES>                                28,126
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 471
<INCOME-PRETAX>                                (2,173)
<INCOME-TAX>                                       700
<INCOME-CONTINUING>                            (2,873)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (2,873)
<EPS-PRIMARY>                                   (0.22)
<EPS-DILUTED>                                   (0.22)
        

</TABLE>
DecaBDE Phase-out Initiative| Existing Chemicals | OPPT | US EPA

http://www.epa.gov/oppt/existingchemicals/pubs/actionplans/deccadbe.html[8/15/2012 1:50:27 PM]

EPA Home Privacy and Security Notice Contact Us

http://www.epa.gov/oppt/existingchemicals/pubs/actionplans/deccadbe.html

Print As-Is

Last updated on Wednesday, July 25, 2012

You are here: EPA Home Chemical Safety and Pollution Prevention Pollution Prevention & Toxics Existing

Chemicals DecaBDE Phase-out Initiative

Existing Chemicals

Contact Us Search: All EPA This Area

DecaBDE Phase-out Initiative

On December 17, 2009, as the result of negotiations with EPA, the two U.S. producers of

decabromodiphenyl ether (decaBDE), Albemarle Corporation and Chemtura Corporation, and the

largest U.S. importer, ICL Industrial Products, Inc., announced commitments to phase out decaBDE

in the United States.

DecaBDE is a flame retardant which has been used in electronics, wire and cable insulation,

textiles, automobiles and airplanes, and other applications.

The companies have committed to end production, importation, and sales of decaBDE for most

uses in the United States by December 31, 2012, and to end all uses by the end of 2013. The

company commitment letters and annual progress reports will be posted to this website.

Steve Owens, EPA Assistant Administrator for the Office of Prevention, Pesticides and Toxic

Substances, issued the following statement in response to the announcement: 

“Though DecaBDE has been used as a flame retardant for years, U.S. Environmental Protection

Agency has long been concerned about its impact on human health and the environment. Studies

have shown that decaBDE persists in the environment, potentially causes cancer and may impact

brain function. DecaBDE also can degrade to more toxic chemicals that are frequently found in the

environment and are hazardous to wildlife. 

“Today’s announcement by these companies to phase out decaBDE is an appropriate and

responsible step to protect human health and the environment.”

EPA intends to encourage the other minor importers of decaBDE to join this initiative.

Company Commitment Letters

Albemarle Corporation (PDF) (2 pp., 403 kb)

Chemtura Corporation (PDF (2 pp., 34kb)

ICL Industrial Products, Inc. (PDF) ( 2 pp., 55 kb)

DecaBDE is a polybrominated diphenyl ether (PBDE). Find out more about PBDEs.

Existing Chemicals

 Home

Basic Information

Enhancing EPA's

Chemicals

Management

Program

Managing Chemical

Risk

Collecting and

Assessing

Information on

Chemicals

Transparency:

Finding Public

Information on

Chemicals

International

Activities

Related EPA

Activities

Chemical

Characterizations

Recent

Announcements

Share
|SECURITIES AND EXCHANGE
COMMISSION
|----------------------------------



|Washington, D.C. 20549
|----------------------



|FORM 8-K  CURRENT REPORT
|------------------------



|Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
|----------------------------------------------------------------------



|Date of Report (date of earliest
event reported): February 25, 2003
|-------------------------------------------------------------------



|BRADLEY PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|------------------------------------------------------------------------------------



|Delaware 
      (State or other 
      jurisdiction of incorporation) | 0-18881 
      (Commission File Number) | 22-2581418 
      (IRS Employer  
      Identification No.)
|--------------------------------------------------------------------- | --------------------------------------- | -----------------------------------------------------------





|383 Route 46 West, Fairfield, New Jersey
      (Address of principal executive office) | 07004
      (Zip Code)
|-------------------------------------------------------------------------------------- | ----------------------





|Registrants telephone number,
including area code: (973) 882-1505
|------------------------------------------------------------------



| |  | 
| |  | 



---





|Item 5.  Other Events
|---------------------



|On February 25,
2003, Bradley Pharmaceuticals, Inc. filed a complaint against DPT Lakewood, Inc., a
wholly owned subsidiary  of DPT Laboratories Ltd., in the United States District Court
for the District of New Jersey.  A copy of the related press release is  attached hereto.
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Item 7.  Financial Statements and Exhibits
|------------------------------------------



|(c)  Exhibits
|-------------



|99.1- | Press Release by Bradley Pharmaceuticals,
      Inc. dated February 25, 2003
|----- | ----------------------------------------------------------------------------





|SIGNATURE
|---------



|Pursuant to the
requirements of the Securities Exchange Act of 1934,  the Registrant has duly caused this
report to be signed on its behalf by the  undersigned hereunto duly authorized.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | BRADLEY PHARMACEUTICALS, INC.
| | -----------------------------





| | By: | /s/ Daniel Glassman
      Daniel Glassman 
      Chairman, President and CEO
| | --- | ----------------------------------------------------------------------------





|Dated:  February 26, 2003
|-------------------------



| |  | 
| |  | 



---
§ 516.24 Granting MUMS-drug designation. ( a ) FDA may grant the request for MUMS-drug designation if none of the reasons described in § 516.25 for refusal to grant such a request apply.
( b ) When a request for MUMS-drug designation is granted, FDA will notify the sponsor in writing and will give public notice of the MUMS-drug designation in accordance with § 516.28.
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7392 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7392

  To reprogram Federal funds appropriated for UNRWA to construct the 
    southwest border wall and to prohibit future funding for UNRWA.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 15, 2024

Mr. Steube (for himself, Mr. Ogles, Mr. Weber of Texas, Mr. Nehls, Mr. 
    Posey, and Mr. Duncan) introduced the following bill; which was 
  referred to the Committee on Appropriations, and in addition to the 
     Committee on Foreign Affairs, for a period to be subsequently 
   determined by the Speaker, in each case for consideration of such 
 provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL

 
  To reprogram Federal funds appropriated for UNRWA to construct the 
    southwest border wall and to prohibit future funding for UNRWA.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. REPROGRAMMING OF AMOUNTS APPROPRIATED FOR UNRWA.

    (a) In General.--Notwithstanding any other provision of law, all 
Federal funds that, as of the date of the enactment of this Act, have 
been appropriated for, but not provided to, the United Nations Relief 
and Works Agency for Palestine Refugees in the Near East shall be made 
available for the construction of a permanent physical barrier along 
the southwest border of the United States.
    (b) Prohibition of Future Funding.--Beginning on the date of the 
enactment of this Act, no Federal funds may be provided to the United 
Nations Relief and Work Agency for Palestine Refugees in the Near East.
                                 <all>
```
This disposition is not appropriate for publication and is not precedent *

except as provided by 9th Cir. R. 36-3.

The panel unanimously concludes this case is suitable for decision **

without oral argument. See Fed. R. App. P. 34(a)(2).

AH/Research

NOT FOR PUBLICATION

UNITED STATES COURT OF APPEALS

 FOR THE NINTH CIRCUIT

ADRIAN MELGOZA,

 Petitioner - Appellant,

 v.

RICHARD KIRKLAND, Associate

Warden,

 Respondent - Appellee.

No. 08-16837

D.C. No. 5:06-cv-04861-JW

MEMORANDUM *

Appeal from the United States District Court

for the Northern District of California

James Ware, District Judge, Presiding

Submitted March 16, 2010** 

Before: SCHROEDER, PREGERSON, and RAWLINSON, Circuit Judges.

California state prisoner Adrian Melgoza appeals from the district court’s

dismissal of his 28 U.S.C. § 2254 habeas petition as untimely filed. We have

jurisdiction pursuant to 28 U.S.C. § 2253, and we reverse and remand. 

FILED

MAR 26 2010

MOLLY C. DWYER, CLERK

U.S. COURT OF APPEALS
AH/Research 08-16837

Melgoza contends that the district court wrongly calculated the due date of

his habeas petition, and that, contrary to the district court’s holding, his habeas

petition was timely filed. As the State commendably acknowledges on appeal, the

district court failed to apply the prisoner mailbox rule, and therefore wrongly

calculated the length of the equitable tolling period. Melgoza is entitled to

additional tolling under the prisoner mailbox rule. See Ramirez v. Yates, 571 F.3d

993, 996 n.1 (9th Cir. 2009) (internal quotations and citations omitted). Thus,

when Melgoza delivered his habeas petition to prison officials on August 8, 2006,

it was timely when the tolling acknowledged by the State is taken into

consideration. See Jorss v. Gomez, 311 F.3d 1189, 1192 (9th Cir. 2002). Because

Melgoza’s federal habeas petition is timely, we reverse the district court’s

judgment dismissing Melgoza’s petition, and remand for further proceedings.

The appointment of counsel shall continue on remand to the district court.

Melgoza’s motion for judicial notice is granted. 

Melgoza’s motions for summary reversal and immediate issuance of the

mandate are denied as moot.

REVERSED AND REMANDED.
N OTE : This disposition is nonprecedential.


# United States **Court of Appeals**  **for the Federal Circuit**

______________________
MICHAEL R. LANGE, AND SKY ROBOTICS, INC., Plaintiffs

- Appellants,

v.

MARK A. LITMAN, AND MARK A. LITMAN & ASSOCIATES, P.A., Defendants

- Appellees,

AND

IPC EAGLE, INC., Defendant.

______________________

2012

- 1565

______________________
Appeal from the United States District Court for the District of Minnesota in No. 11

- CV

- 2387, Judge Donovan W. Frank.

______________________

ON MOTION

______________________

Before D YK
, M AYER
, and O'M ALLEY
, Circuit Judges.

P ER C URIAM

. O R D E RMICHAEL R

. LANGE v. MARK A

. LITMAN 2

On March 11, 2013, appellees Mark A. Litman and Mark A. Litman & Associates filed a motion seeking reversal without oral argument and a remand with i nstructions to dismiss the plaintiff’s malpractice claims for lack of jurisdiction. Appellants Michael R. Lange and Sky Robotics, Inc., opposed.

I T I S O RDERED T HAT : In light of the Supreme Court’s decision in Gunn v. Minton , 568 U.S. ___, 133 S.Ct. 1059 (2013), we conclude that the district court lacked jurisdiction over the ma lpractice claims at issue. We vacate the district court’s decision and remand to the district court. On remand the district court shall dismiss the plaintiffs’ complaint for lack of jurisdiction.

F OR THE C OURT

March 27, 2013 /s/ Jan Horbaly D ate Jan Horbaly Clerk

cc: Paul A. Sortland, Esq. Charles E. Lundberg, Esq.
EXHIBIT 32.1

CERTIFICATION

I, Brian F. Lavin, President of NTS
Capital Corporation, the general partner of NTS-Properties Associates VII, the general partner
of NTS-Properties VII, Ltd. (the Partnership), certify, pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

|1. |  | The quarterly report on Form 10-Q of the Partnership for the period ended September
               30, 2004 (the Report) fully complies with the requirements of
               Section 13(a) of the Securities Exchange Act of 1934, as amended; and
|-- |  | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|2. |  | The information contained in the Report fairly presents, in all material
               respects, the financial condition and results of operations of the Partnership.
|-- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dated: November 15, 2004

/s/ Brian F. Lavin

---

President of NTS Capital Corporation,
General Partner of NTS-Properties Associates VII,
General Partner of NTS-Properties VII, Ltd.

A signed original of this written
statement required by Section 906 has been provided to the Partnership and will be
retained by the Partnership and furnished to the Securities and Exchange Commission or its
staff upon request.
39129.

#### HARRIS EQUIPMENT COMPANY, INC. v. McGUIGAN.

Decided October 11, 1961.

*Divine ■& Busbee, Stow & Andrews, Robert E. Andrews,*for plaintiff in error.

*Telford, Wayne & Smith, Jeff C. Wayne, H. A. Stephens, Jr., W. Dent Aeree, Smith, Field, Ringel, Martin & Carr,*contra.

Eberhardt, Judge.

“The sole assignment of error contained in the bill of exceptions in this case is to the judgment of the trial court overruling the demurrer to the defendant’s answer. Under repeated decisions of this court and of the Supreme Court the bill of exceptions is premature and there being no assignment of error on a final judgment the writ of error must be dismissed. *Sundy v. Allgood,*93 Ga. App. 741 (92 SE2d 726); *Chandler v. Southern Union Conference, 95*Ga. App. 66 (96 SE2d 621); *Stowe v. Columbia Loan Co., 95*Ga. App. 634 (98 SE2d 218).” *Wade v. Ward,*101 Ga. App. 44 (112 SE2d 689). And see *Cox v. Peoples Fin. Serv.,*101 Ga. App. 506 (114 SE2d *293); Etheridge v. Quality Hatchery,*98 Ga. App. 164 (105 SE2d 402); *Shaw v. Miller,*214 Ga. 225 (104 SE2d 128); *Beavers v. Williams,*197 Ga. 9 (28 SE2d 254); *Rivers v. Hollingsworth,*196 Ga. 708 (27 SE2d 330); *Darden v. Roberts,*193 Ga. 637 (19 SE2d 270).

*Dismissed.*

*Carlisle, P. J., and Nichols, J., concur.*
##### 



Exhibit 31.1 CERTIFICATION REQUIRED BY
RULE 13a-14(a) OR RULE 15d-14(d) AND UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002  I, Joseph J. Ueberroth, certify that:  1.
    
    I have reviewed this Annual Report on Form 10-K/A of Ambassadors
International, Inc.;2.
    
    Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period
covered by this report;3.
    
    Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all
material respects the financial condition, results of operations and
cash flows of the registrant as of, and for, the periods presented in
this report;4.
    
    The registrants other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
registrant and have:  (a)
    
    Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;(b)
    
    Evaluated the effectiveness of the registrants disclosure
controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such
evaluation; and(c)
    
    Disclosed in this report any change in the registrants
internal control over financial reporting that occurred during the
registrants most recent fiscal quarter (the registrants fourth
fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the
registrants internal control over financial reporting; and  5.
    
    The registrants other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrants auditors and the audit committee of the
registrants board of directors (or persons performing the equivalent
functions):  (a)
    
    All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial
information; and(b)
    
    Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrants
internal control over financial reporting. March 29, 2004 /s/ Joseph J. Ueberroth
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-END>                               SEP-30-1996
<CASH>                                             132
<SECURITIES>                                         0
<RECEIVABLES>                                  683,752
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                               697,514
<PP&E>                                               0
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 697,514
<CURRENT-LIABILITIES>                        2,160,894
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    205,000
<COMMON>                                         2,013
<OTHER-SE>                                 (1,662,680)
<TOTAL-LIABILITY-AND-EQUITY>                   697,514
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                               456,313
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           (578,611)
<INCOME-PRETAX>                              (480,051)
<INCOME-TAX>                                     (800)
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                 (480,851)
<EPS-PRIMARY>                                   (0.37)
<EPS-DILUTED>                                        0
        

</TABLE>
----------

                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                   ----------

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

                                   ----------

         Date of Report (Date of earliest event reported): May 28, 2001

                     First India Diversified Holdings, Inc.
             (Exact name of registrant as specified in its charter)

                                    New York
                 (State or other jurisdiction of incorporation)

                  000-29193                              06-1551283
           (Commission File Number)           (IRS Employer Identification No.)

     257-10 Union Turnpike, Floral Park, NY                11004
    (Address of principal executive offices)            (Zip Code)

                                  888-238-6400
              Registrant's telephone number, including area code:

         (Former name or former address, if changed since last report.)


<PAGE>

Item 5. Other Information

     The purpose of this filing is to correct any impression on the part of the
readers of any of the Company's prior filings that the company was ever a "blank
check" company as that term is defined under the securities laws and
regulations. The Company initiated business as an ethnic Indian Food products
enterprise. That business failed. After a period of business dormancy, the
company entered into an agreement to acquire the ground meat products division
of Maggio Beef Corp. based on finalizing negotiations on certain account
receivable financing. The Company intends to change its name to MBC Food Corp.
upon the completion of the transaction.


<PAGE>

                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant has duly caused this report on Form 8-K to be signed on its behalf by
the undersigned hereunto duly authorized.

                                          First India Diversified Holdings, Inc.

                                          By: /s/ David Griffith
                                             -----------------------------
                                             David Griffith, President



Date:      August 27 , 2001
     ---------------------------